AusBiotech is pleased to announce an expanded investment attraction offering has commenced in line with a new investment attraction strategy.
This strategy was developed in response to feedback from members and industry stakeholders during the development of the Biotechnology Blueprint; A Decadal Strategy for the Australian Biotechnology Industry.
AusBiotech recognises that access to capital is one of the most significant drivers of growth and sustainability for Australia's life sciences sector. In the context of explosive growth in company numbers and a focus on commercialisation, the appetite for capital within our sector is accelerating.
As Australia's peak industry membership body, AusBiotech will continue to take a leadership role in promoting the sector to potential investors, building investment capability within the sector, and delivering a range of initiatives that aim to increase and diversify the flow of funding into the Australian life sciences sector.
To drive this expanded portfolio, Lisa Renkin has recently joined AusBiotech as Director, Investment. Lisa is well known to many in the sector and has worked collaboratively with AusBiotech and sector stakeholders over many years. Most recently Lisa was the Victorian Deputy Commissioner to China with responsibility for the investment attraction portfolio. Prior to that appointment she worked at the Burnet Institute, leading various commercialisation activities including the expansion of the Institute's China programme, and contributing to AusBiotech's global investment programme in an advisory capacity.
The investment programme will build on AusBiotech’s successful investment series that has brought together investors and Australian companies seeking capital over the past decade - and will bolster the evidence base and industry-level analysis available by refreshing and creating new resources.
The work will commence with the development of an environmental, social, and governance (ESG) framework to support reporting for the industry, as it is increasingly important to AusBiotech employees, members and industry stakeholders, including investors, and is strongly aligned with community expectations.
To continue this investment discussion, AusBiotech encourages you to register for AusBioInvest 2022 on 27 October 2022 in Perth, WA.